Biolinerx Ltd ADR (BLRX)

$3.72 +0.06 (1.64%)
Market Cap 16.19M
Revenue (ttm) 28.94M
Net Income (ttm) -9.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.86%
Debt to Equity Ratio 0.56
Volume 15,900
Avg Vol 38,894
Day's Range N/A - N/A
Shares Out 4.35M
Stochastic %K 36%
Beta 1.25
Analysts Strong Sell
Price Target $26.00

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
gargoyl
gargoyl Oct. 23 at 7:53 PM
🐎 $BLRX and 🐎 $VSTM have trials with GenFleet Therapeutics for PDAC with different mechanisms of action , different target groups and are at different stages of progression along phases and trials …. Long the 🦋 👇$REGN
0 · Reply
gargoyl
gargoyl Oct. 21 at 7:43 PM
$BLRX 👀 can’t wait for Gloria to drop a 🐈‍⬛ catalyst… $$ $REGN $PFE Long the 🦋
0 · Reply
tankwfwf
tankwfwf Oct. 19 at 8:48 PM
$BLRX save your self some headaches and get out of this scam, Phil is worse than a shit eating fly.......check out LAES AND MAKE SOME MONEY.........
0 · Reply
gargoyl
gargoyl Oct. 16 at 5:35 PM
$BLRX 👀 not if , it’s when the next catalyst pops .. Phil 🥷🏿 has built a foundation over the years that will see exponential growth. 🎯 Target $12 before end year . $REGN $PFE $XBI 👇
0 · Reply
Eran1983
Eran1983 Oct. 16 at 8:32 AM
$BLRX the CEO of this company took money from many shareholders. Until he will bring this company to 20 X share value no respect to this man
3 · Reply
gargoyl
gargoyl Oct. 15 at 3:30 PM
$BLRX 👀 pg. 16 BiolineRx Corp. Presentation speaks volumes, the link below shares pipeline as well as BLRX stake of 40% increases in JV w/ Hemispherian as it contributes $$ to devmnt, sheer genius Phil 🥷🏿 up to 70% Then there's Gloria & Ayrmid/Gamida Partnerships w/ APHEXDA revenue and catalysts, not to mention Columbia Univ., Washington Univ. and St Jude Children’s Research Hospital collaborations on PDAC and Sickle Cell diseases and cancer. Long the 🦋 $REGN $$PFE Currently 16M Corp valuation is off by 10x 🎯, watch this !!!! Mark this post . https://ir.biolinerx.com/static-files/f1fbb06b-cb0e-4902-b166-f780a049ba38
0 · Reply
gargoyl
gargoyl Oct. 13 at 7:25 PM
$BLRX spread wide off charts 📈 She’s about to run 👀 🏃‍♀️ $XBI $IBB
0 · Reply
Halbalidiya
Halbalidiya Oct. 13 at 1:20 PM
$BLRX gargoyl is phil
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 6:54 PM
Results of list 9/26/25 $BLK $BLKB $BLMN $BLRX Cycle Trading Signal plugged into AI 🔥 list.
0 · Reply
gargoyl
gargoyl Oct. 8 at 10:10 PM
$BLRX a “ W “ formation calculation from the center spike to the low calculation implies a .75 cent move to $5.25 and possibly more if it’s not just charting and an entity is accumulating.. let’s see tomorrow.. long the 🦋 $XBI pop perfect storm
0 · Reply
Latest News on BLRX
BioLineRx Ltd. - Special Call

Sep 29, 2025, 3:27 PM EDT - 26 days ago

BioLineRx Ltd. - Special Call

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Sep 29, 2025, 7:00 AM EDT - 26 days ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 10:44 AM EDT - 2 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 2 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Aug 7, 2025, 7:00 AM EDT - 2 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 1:58 PM EDT - 5 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 30, 2025, 7:00 AM EDT - 5 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 12:55 PM EDT - 5 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 27, 2025, 7:00 AM EDT - 5 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

May 20, 2025, 7:00 AM EDT - 5 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:52 AM EDT - 7 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:00 AM EDT - 7 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report 2024 Annual Results on March 31, 2025

Mar 24, 2025, 7:00 AM EDT - 7 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

BioLineRx Issues Letter to Shareholders

Jan 21, 2025, 7:00 AM EST - 9 months ago

BioLineRx Issues Letter to Shareholders

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 17, 2025, 7:00 AM EST - 10 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 2:01 PM EST - 10 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

BioLineRx Announces $10 Million Registered Direct Offering

Jan 6, 2025, 8:57 AM EST - 10 months ago

BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 10:58 AM EST - 11 months ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 25, 2024, 7:00 AM EST - 11 months ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx: Still A Buy, With Some Questions

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

Dec 2, 2023, 11:25 PM EST - 2 years ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 1:54 PM EST - 2 years ago

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 20, 2023, 7:00 AM EST - 2 years ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

gargoyl
gargoyl Oct. 23 at 7:53 PM
🐎 $BLRX and 🐎 $VSTM have trials with GenFleet Therapeutics for PDAC with different mechanisms of action , different target groups and are at different stages of progression along phases and trials …. Long the 🦋 👇$REGN
0 · Reply
gargoyl
gargoyl Oct. 21 at 7:43 PM
$BLRX 👀 can’t wait for Gloria to drop a 🐈‍⬛ catalyst… $$ $REGN $PFE Long the 🦋
0 · Reply
tankwfwf
tankwfwf Oct. 19 at 8:48 PM
$BLRX save your self some headaches and get out of this scam, Phil is worse than a shit eating fly.......check out LAES AND MAKE SOME MONEY.........
0 · Reply
gargoyl
gargoyl Oct. 16 at 5:35 PM
$BLRX 👀 not if , it’s when the next catalyst pops .. Phil 🥷🏿 has built a foundation over the years that will see exponential growth. 🎯 Target $12 before end year . $REGN $PFE $XBI 👇
0 · Reply
Eran1983
Eran1983 Oct. 16 at 8:32 AM
$BLRX the CEO of this company took money from many shareholders. Until he will bring this company to 20 X share value no respect to this man
3 · Reply
gargoyl
gargoyl Oct. 15 at 3:30 PM
$BLRX 👀 pg. 16 BiolineRx Corp. Presentation speaks volumes, the link below shares pipeline as well as BLRX stake of 40% increases in JV w/ Hemispherian as it contributes $$ to devmnt, sheer genius Phil 🥷🏿 up to 70% Then there's Gloria & Ayrmid/Gamida Partnerships w/ APHEXDA revenue and catalysts, not to mention Columbia Univ., Washington Univ. and St Jude Children’s Research Hospital collaborations on PDAC and Sickle Cell diseases and cancer. Long the 🦋 $REGN $$PFE Currently 16M Corp valuation is off by 10x 🎯, watch this !!!! Mark this post . https://ir.biolinerx.com/static-files/f1fbb06b-cb0e-4902-b166-f780a049ba38
0 · Reply
gargoyl
gargoyl Oct. 13 at 7:25 PM
$BLRX spread wide off charts 📈 She’s about to run 👀 🏃‍♀️ $XBI $IBB
0 · Reply
Halbalidiya
Halbalidiya Oct. 13 at 1:20 PM
$BLRX gargoyl is phil
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 6:54 PM
Results of list 9/26/25 $BLK $BLKB $BLMN $BLRX Cycle Trading Signal plugged into AI 🔥 list.
0 · Reply
gargoyl
gargoyl Oct. 8 at 10:10 PM
$BLRX a “ W “ formation calculation from the center spike to the low calculation implies a .75 cent move to $5.25 and possibly more if it’s not just charting and an entity is accumulating.. let’s see tomorrow.. long the 🦋 $XBI pop perfect storm
0 · Reply
gargoyl
gargoyl Oct. 8 at 4:38 PM
$BLRX 👀 my little brother hasn’t been around in a while. He is so special. He sees things, patterns, deep correlations, algo sh$T. He walked into my trading room , pointed to this chart 📊 and said go long , average in, he likes the SP action, the volume steadying, the chart itself over different time frames is at a pivotal point … He’s 11 years old .. a savant maybe or just wired for technical numbers and the past vs the future pattern. $XBI $IBB $REGN
0 · Reply
gargoyl
gargoyl Oct. 8 at 6:47 AM
$BLRX 👀 $5.50 🎯 this week 2 of 2 $XBI
0 · Reply
gargoyl
gargoyl Oct. 8 at 6:44 AM
$XBI 1 of 2 $BLRX 👇
0 · Reply
gargoyl
gargoyl Oct. 7 at 5:30 PM
$BLRX 👀 3 of 3 Longest the 🦋
0 · Reply
gargoyl
gargoyl Oct. 7 at 5:29 PM
$BLRX 👀 2 of 3 Long the 🦋
0 · Reply
gargoyl
gargoyl Oct. 7 at 5:28 PM
$BLRX 👀 1 of 3
0 · Reply
edvquye
edvquye Oct. 7 at 3:37 PM
$BLRX
0 · Reply
gargoyl
gargoyl Oct. 7 at 3:28 PM
$BLRX life is good now , always go with instinct, then do your DD .. in end truth rises. Over & Out. ✊
0 · Reply
gargoyl
gargoyl Oct. 6 at 7:53 PM
$BLRX shhhh quietly unnoticed like the glint in Mona Lisa’s eye , or that lip that can communicate volumes with just a thought from the mind to a message through that smile , walk lightly 👂 hear something is happening…
0 · Reply
RRCORNER
RRCORNER Oct. 5 at 10:36 PM
$CRKN $BLRX $ACON $PPCB
0 · Reply
tankwfwf
tankwfwf Oct. 3 at 1:55 PM
$BLRX If you look up who pays for the articles BeyondSPX Research writes it is paid for by the subject companies. So this fluff piece is probably lacking truth.......
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:47 AM
$BLRX Outstanding article that hits the mark on BLRX's current state. So if you want to refresh your BLRX insights or learn about BLRX from scratch, this is a must read. https://beyondspx.com/quote/BLRX/analysis/biolinerx-a-lean-biotech-forging-a-new-path-with-motixafortide-and-pipeline-expansion-nasdaq-blrx
0 · Reply